Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness

被引:85
作者
Kreyenbuhl, Julie
Dickerson, Faith B.
Medoff, Deborah R.
Brown, Clayton H.
Goldberg, Richard W.
Fang, LiJuan
Wohlheiter, Karen
Mittal, Leena P.
Dixon, Lisa B.
机构
[1] Univ Maryland, Sch Med, Dept Psychiat, Div Res Serv, Baltimore, MD 21201 USA
[2] Mental Illness Res Educ & Clin Ctr, VA Capitol Hlth Care Network VISN 5, Baltimore, MD USA
[3] Sheppard Pratt Hlth Syst, Dept Psychol, Baltimore, MD USA
[4] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA
关键词
type; 2; diabetes; serious mental illness; cardiovascular risk; metabolic syndrome;
D O I
10.1097/01.nmd.0000221177.51089.7d
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cardiovascular disease is the leading cause of death in Type 2 diabetes, which commonly occurs in patients with serious mental illnesses (SMIs). We determined the extent to which patients with diabetes and SMI, relative to diabetes patients without SMI, met American Diabetes Association goals for cholesterol and blood pressure, met criteria for the metabolic syndrome, and were prescribed medications known to reduce cardiovascular events. We found that less than half of diabetes patients, both with and without SMI, met recommended goals for cholesterol levels; even fewer had adequate blood pressure control. In addition, a substantial proportion of all diabetes patients met metabolic syndrome criteria. However, diabetes patients with SMI were less likely to be prescribed cholesterol-lowering statin medications, angiotensin-converting enzyme inhibitors, and angiotensin receptor blocking agents than diabetes patients without SMI. Patients with both diabetes and SMI are treated less aggressively for high cardiovascular risk than diabetes patients without mental disorders.
引用
收藏
页码:404 / 410
页数:7
相关论文
共 44 条
[1]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[2]  
2-S
[3]  
Allison DB, 1999, AM J PSYCHIAT, V156, P1686
[4]  
*AM DIAB ASS, 2004, DIABETES CARE S1, V27, pS15
[5]  
*AM DIAB ASS, 2003, DIABETES CARE, V6, P917
[6]   Cardiovascular outcomes among participants with diabetes in the recent large statin trials [J].
Armitage, J ;
Bowman, L .
CURRENT OPINION IN LIPIDOLOGY, 2004, 15 (04) :439-446
[7]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[8]   Causes of the excess mortality of schizophrenia [J].
Brown, S ;
Inskip, H ;
Barraclough, B .
BRITISH JOURNAL OF PSYCHIATRY, 2000, 177 :212-217
[9]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[10]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696